In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...
News-Medical.Net on MSN
Taking anticoagulants alongside prostate cancer drugs does not increase bleeding risk
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
In 3 clinical trials investigating the use of androgen receptor pathway inhibitors (ARPIs) in nonmetastatic castration-resistant prostate cancer (nmCRPC), the primary endpoint of metastases-free ...
Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer ...
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
Performance and Operational Feasibility of Epstein-Barr Virus–Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches Activation of the androgen ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Sex differences are widespread across human development, physiological processes, and diseases, making it important to characterize the impact of sex differences in these areas. Understanding the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results